Transcenta will hold 3 exchange sessions on Post-SITC Business Update Call & TST003 Data Release and Pipeline Development Progress Update

SUZHOU, China, November 9, 2022 /PRNewswire/ — Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical-stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacturing of antibody-based therapeutics, announces the formation of the management team will work with major brokerage firms and asset management firms to organize three exchange sessions November 2022 as follows:

1) Transcenta TST003 data release and pipeline development progress update
time: Thursday, 11/10/2022 10:00 HKT
Guosen Securities Online Public Meeting
Organizer: Transcenta Holding Limited & Guosen Securities

2) 2022 Post-SITC Business Update Call for Investors
Time: Monday, 11/14/2022 8:00 p.m HKT
Public online meeting (English)
Organizer: Transcenta Holding Limited

3) 2022 Post-SITC Business Update Call for Investors
Time: Monday, 11/15/2022 8:00 p.m HKT
Industrial Securities Online Public Meeting
Organizer: Transcenta Holding Limited & Industrial securities

About TST003
TST003 is a high affinity monoclonal antibody against Gremlin1, a member of the TGFb superfamily. The Gremlin1 protein is a highly conserved secreted protein and has been shown to play an important role during development. Gremlin1 is highly upregulated in several solid tumors. The Gremlin1 protein promotes the epithelial-mesenchymal transition. TST003 has shown promising single-agent activity in patient-derived xenograft tumor models of several difficult-to-treat checkpoint inhibitor-resistant solid tumors, including castration-resistant prostate cancer and microsatellite-stable colorectal cancer. TST003 also potentiated the antitumor activity of the checkpoint inhibitor in the syngeneic tumor model. TST003 has received FDA approval to enter clinical testing in September 2022.

About Transcenta Holding Limited
Transcenta (HKEX: 06628) is a clinical-stage biopharmaceutical company with fully integrated capabilities in the discovery, research, development and manufacturing of antibody-based biotherapeutic compounds.

Transcenta has established a global presence with headquarters and Discovery, a clinical and translational research center in Suzhou, a process and product development center and a manufacturing facility in Suzhou HangzhouClinical development centers in PrincetonUS, Beijing, shanghaiand Canton in Chinaas well as Boston and external partner centers in Los Angeles.

Transcenta has also initiated the construction of the corporate headquarters and the second high-end biopharmaceutical plant with ICB as the core technology in the Suzhou Industrial Park. Transcenta is developing ten therapeutic antibody molecules for oncology and select non-oncology indications, including bone and kidney diseases.

For more information, please visit

www.transcenta.com and https://www.linkedin.com/company/transcenta.

decision

decision

View original content: https://www.prnewswire.com/news-releases/transcenta-to-hold-3-exchange-sessions-on-post-sitc-business-update-call–tst003-data-release-and – Pipeline Development Progress Update-301672953.html

SOURCE Transcenta Holding Limited

source

Leave a Reply

Your email address will not be published. Required fields are marked *